Tafinlar® (dabrafenib) and Mekinist® (trametinib), both made by Novartis, are now approved for combination use to treat unresectable or metastatic solid tumors with BRAF V600E mutation in patients who are at least six years old and have disease progression following prior treatment, with no satisfactory alternative treatment options.

• Both medications have held FDA approval since 2013. They are indicated to treat multiple forms of cancer in patients who have a BRAF mutation.
• The recommended dosage of Tafinlar is 150mg twice daily for adults and based on body weight in children. Recommended dosing for Mekinist is 2mg once daily for adults and based on body weight in children. Both medications are taken by mouth at least one hour before or two hours after a meal.